List of Roszet drug patents

Roszet is owned by Althera Pharms.

Roszet contains Ezetimibe; Rosuvastatin Calcium.

Roszet has a total of 2 drug patents out of which 0 drug patents have expired.

Roszet was authorised for market use on 23 March, 2021.

Roszet is available in tablet;oral dosage forms.

Roszet can be used as treatment of hyperlipidemia.

The generics of Roszet are possible to be released after 01 May, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376470 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
May, 2033

(10 years from now)

US9763885 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
May, 2033

(10 years from now)

Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 23 March, 2021

Treatment: Treatment of hyperlipidemia

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in